Women with genetic cancer risk being ‘missed' due to testing gaps
Families of some cancer patients are being denied the chance to find out about their cancer risk due to gaps in genetic testing, a new study has suggested.
A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said.
Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries.
It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth.
Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS.
If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family.
A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing.
Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023.
They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team.
This means that follow-up genetic counselling and blood tests were not always arranged.
Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology.
Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test.
Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected.
Family members are also left vulnerable to cancer risk, unaware they may have the condition.
Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way.
'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected.
'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
This 10-year plan may be the last chance to save the NHS
The 10-year plan for the National Health Service that Sir Keir Starmer is expected to publish in the next few days is likely to be a somewhat incoherent document. From the advance publicity, it would seem to have a lot of disconnected ideas in it, some good, some not so good and some irrelevant. The government hopes that weight-loss drugs will offer the hope of a big advance against obesity-related illnesses – but this comes after new figures raised concerns about their safety. If large language models can speed up the development of new pharmaceuticals, so much the better. But we remain sceptical about whether supermarkets ought to be recruited into policing their customers' calorie intakes. What will decide the success or failure of the NHS over the next decade, however, will be the design of the structural reforms to the service. Wes Streeting, the health and social care secretary, has made a good start in two respects. He has welcomed private-sector providers to help deliver NHS services free at the point of need, and he has taken an axe to the central bureaucracy of NHS England. The test for the 10-year plan will be the extent to which it brings in further changes to incentives throughout the NHS so that it becomes responsive to patients. Sir Jim Mackey, the new chief executive of the NHS, says many of the right things. 'It feels like we've built mechanisms to keep the public away because it's an inconvenience,' he says in his first interview since taking up the post three months ago. He says of the current NHS: 'It takes forever. It costs a fortune. We need to 'de-layer it' because it's expensive, it slows decision-making down, it de-powers people who need to make decisions.' The sentiment is right, but again, some of his ideas seem better than others. We are not convinced that using patient satisfaction surveys to decide how much money NHS trusts receive is going to work. The evidence of reform under the last Labour government was that the mere existence of competition from private-sector providers had a dramatic effect on the performance of NHS units. Already, there are the very early signs that the extra resources put into the NHS are bearing fruit, less than 12 months after the change of government. Luke Tryl, the opinion pollster for More in Common, reported on BBC's Newsnight on Friday that people in focus groups are starting to report positive experiences of the NHS for the first time since the pandemic. 'If there is a bright spot for the government, it's the NHS,' he said. One of the biggest challenges for Sir Jim and Mr Streeting, however, is more political than structural. They have to send the starkest message to doctors: please do not go on strike; take responsibility; show leadership; it is up to you to make the NHS work, because if it cannot be turned round this time, then it probably is the end of this model of healthcare. Sir Jim appears to understand this. He says that his 'big worry' is that if the NHS cannot deliver a service that is better at listening to patients – the particular example he gave was maternity care – 'we'll lose the population; if we lose the population, we've lost the NHS; for me, it's straightforward: the two things are completely dependent on each other.' He is absolutely right. Universal healthcare free at the point of need is a noble idea, but it desperately needs Labour's reforms to work if it is to survive.
The Sun
2 hours ago
- The Sun
Taxpayer cash spent on studying whiteness and helping women called ‘witches'
TAXPAYERS' cash is being blown on studying whiteness in South America and helping women called 'witches' to sing, a dossier reveals. An investigation found £16.5 million is being spent on 21 'woke' research projects at UK unis. They include almost £85k on a Newcastle University project called 'Combating Witchcraft-Related Violence through Song'. It looks at how singing helps elderly women in South Africa abused for being a 'witch' due to their ageing features. Over £1million has been earmarked for a University of Nottingham project 'decolonising' photos from British Malaya. A further £246k has been put aside for Sheffield University to develop a city tour app exploring 'whiteness' in statues and monuments in Chile. Nearly £783k is being spent by Queen Mary University of London on a scheme looking at 'Military Decarbonisation'. And £379k is going towards a Birkbeck College programme on children's crafting in West Africa. Cash was handed out by quango UK Research and Innovation. They were uncovered by founder of Doge UK Charlotte Gill, who said taxpayers will be 'fuming' to see where their cash goes. She said: 'Unfortunately this is just the tip of the iceberg, with thousands of similar taxpayer-funded grants being awarded under the UKRI - never mind the vast sums spent on the rest of the public sector.' A UKRI spokesperson said: 'International research collaboration is vital to help us tackle global challenges in a complex and interconnected world, improving security and prosperity in the UK and internationally. "Projects are prioritised for funding through independent expert peer review, as set out in the Higher Education and Research Act.'
The Sun
2 hours ago
- The Sun
From mushrooms to guarana – three products to help you prevent dehydration
AS I've signed up to this summer's Manchester Half marathon I'm going to be doing some (sweaty) training, so prioritising hydration is crucial. When we sweat we don't just lose water but vital minerals such as sodium, potassium and calcium too. Maintaining their balance is vital to prevent dehydration and electrolytes are key. I've put three – which also have added extras – to the test. PROTEIN ELLE Macpherson's company WelleCo has released The HydroProtein Elixir. In addition to 15g of pea protein per serving it has electrolytes (sodium, potassium and magnesium) for hydration, and a beauty blend (vitamin C, hyaluronic acid, niacin and biotin) for glowing skin. It's also got vitamin B5 for energy. The blackcurrant and pomegranate flavour had a refreshing sharpness. I love that this is a great mixture of ingredients and just 63 calories per serving. The HydroProtein Elixir, £35, MUSHROOMS FOURFIVE is a new firm founded by professional rugby players George Kruis and Dom Day. Their Hydro Hydration Energy and Focus drink contains five key electrolytes calcium, potassium, chloride, magnesium and sodium as well as lion's mane mushrooms and ginseng which help with energy, focus and mental clarity. This also has eight B vitamins and 76mg of caffeine which is about the same as a cup of instant coffee but also contains an amino acid called L-theanine which stops you feeling jittery after caffeine. The Hydro Energy and Focus powder is Red Berry flavour – which is delightful, not too sharp or sweet – and comes as a single, 7-pack or 30-pack sachets (5.5g) from about £1.10 a sachet. From Holland & Barrett or Nell McAndrew's marathon guide GUARANA MUCH more than just another energy drink, Phizz Daily Energy, features a specialised hydration formula and a high-strength, scientifically formulated B-vitamin complex. B-vitamins are important in helping your body convert food into energy, supporting everything from brain function to helping to reduce tiredness and fatigue. Plus, with a blend of caffeine and guarana extract, it provides 75mg of caffeine per tablet. Guarana berries contain three times more caffeine than coffee but it's released slowly, meaning Phizz Daily Energy provides sustained energy over time. They cost £7.99 for a tube of x 20 tablets. For more information, see
